Objective: To study the effect of Maxing Shigan Tang combined with azithromycin on anti-inflammatory and pro-inflammatory cytokines and immune function of children with mycoplasmal pneumoniae pneumonia (MPP). Method: A total of 165 cases of children with MPP treated at our hospital from November 2014 to April 2016 were selected and divided into two groups according to the random number table

with 83 cases in clinical group and 82 in control group. Patients in control group were treated with azithromycin sequential therapy

while clinical group was given Maxing Shigan Tang combined with azithromycin sequential therapy. Result: The total effective rate of clinical group was 93.98%

which was 81.71% in control group

indicating that clinical group was superior to control group (P<0.05). Compared with before treatment

interleukin (IL)-4 and IL-10 of two groups were decreased

while IL-2 was increased after treatment (P<0.05). Compared with control group

the levels of IL-4 and IL-10 in patients of clinical group were lower

while IL-2 was higher after treatment (P<0.05). The levels of IL-6

tumor necrosis factor-α(TNF-α) and interferon-γ (IFN-γ) of two groups showed significant differences before and after treatment. The level of inflammatory factor in the clinical group was lower than in the control group (P<0.05). Compared with before treatment

CD8+and RBC-ICR of two groups were decreased

while CD3+

CD4+and RBC-C3bR were increased after treatment (P<0.05). Compared with control group

the levels of CD8+and RBC-ICR in patients of clinical group were lower

while CD3+

CD4+and RBC-C3bR were higher after treatment (P<0.05). Compared with control group

TCM syndrome score of clinical group was lower

with statistically significant differences (P<0.05). Conclusion: Maxing Shigan Tang is very effective in treating MPP children. It can significantly improve anti-inflammatory factors

reduce pro-inflammatory cytokines

and improve the immune function.